Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax Inc. is maintaining a positive outlook as it has slightly increased its FY25 revenue framework from $1-$1.05 billion to $1.04-$1.06 billion, bolstered by anticipated milestone earnings and marketing authorization transfers. The company's working capital has improved significantly to $544.7 million, providing additional liquidity to fund operations and focus on core competencies. Furthermore, strategic cost reduction initiatives are projected to yield approximately $230 million in savings over the next 11 years, enhancing financial stability and operational efficiency.

Bears say

Novavax Inc is experiencing a significant downturn in its financial outlook, highlighted by a $160M decrease in cash equivalents during 2024, which raises concerns about operational sustainability amid ongoing cash burn. The company has reported a 17% year-over-year revenue decline due to the transition of lead commercial responsibility to Sanofi beginning with the upcoming COVID season, leading to substantial reductions in income. Furthermore, the potential failure of its vaccine candidates, such as NanoFlu, to differentiate from existing options poses a risk to their competitiveness, which could negatively impact future revenue generation and overall valuation.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.